Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Lifecore Biomedical, Inc. \De\ Q3 2026 Results: Net Loss of $40.1M, Loss Widens

Lifecore Biomedical reported a significant net loss of $61.2 million for the nine months ended September 30, 2026, compared to a $20.9 million loss in the prior year, primarily driven by a $35.6 million non-cash change in the fair value of a related party debt derivative. Total revenues decreased to $82.7 million from $105.7 million year-over-year, and the company recently entered into a merger agreement with affiliates of Webster Equity Partners.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue25.331.1
Gross profit6.87.8
Profit before tax-40.0-9.7
Net income-40.1-10.0
EPS (diluted, $ a share)$-1.08$-0.29

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-18.6%
Gross margin27.0%
Operating margin-3.5%
Source

10-Q filed with the SEC, NASDAQ: LFCR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Lifecore Biomedical, Inc. \De\: key numbers

Share price
$6.41Close, Nov 16
Market cap
$243M
Shares outstanding
37.91MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Lifecore Biomedical, Inc. \De\

All →
8:03 AM ET 8-K
M&A Deal

Lifecore Biomedical, Inc. \De\ M&A Deal with Lifecore Inc.

Lifecore Biomedical announced that the Department of Justice and the Federal Trade Commission granted early termination of the HSR Act waiting period for its pending merger with Lifecore Inc. This satisfies a key regulatory closing condition for the transaction, which remains subject to stockholder approval and other customary conditions. Lifecore Biomedical will become a wholly owned subsidiary of Lifecore Inc. upon completion of the deal.

Counterparty
Lifecore Inc.
7:14 AM ET 8-K
Financial Results

Lifecore Biomedical, Inc. \De\ Financial Results

Lifecore Biomedical reported Q3 2026 financial results, showing a revenue decrease of 18.6% to $25.3 million compared to the prior year. The company reported a net loss of $40.1 million, or $1.08 per diluted share, while highlighting several new business wins in its CDMO pipeline including technology transfer projects and development-phase programs.

Term
Q3 2026

“During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualification (PPQ) batches for a biotech company’s new drug application (NDA) for a new chemical entity, and the other will support a currently marketed product for a large pharmaceutical company. We believe these programs will add to Lifecore’s high-value pipeline, and we expect each to contribute to the company’s long-term revenue growth objectives, beginning in 2027”

Paul Josephs, president and chief executive officer of Lifecore
4:31 PM ET 8-K
M&A Deal

Lifecore Biomedical, Inc. \De\ M&A Deal with Lifecore Inc.

Lifecore Biomedical established November 4, 2026, as the record date for a special meeting of stockholders to vote on its previously announced merger agreement with Lifecore Inc. and Hazel Merger Sub, Inc. The company will file a proxy statement to solicit shareholder approval for the adoption of the merger agreement.

Counterparty
Lifecore Inc.
4:12 PM ET 8-K
Contract Win

Lifecore Biomedical, Inc. \De\ Wins Contract from Alcon Research, LLC

Lifecore Biomedical extended its contract manufacturing agreement with Alcon Research, LLC, pushing the expiration date from 2031 to December 31, 2034. The amendment establishes Alcon's minimum purchase obligations through the new term and includes a non-compete provision regarding certain products starting in November 2026.

Counterparty
Alcon Research, LLC
Term
through Dec 2034
8:54 AM ET 8-K
M&A Deal

Lifecore Biomedical, Inc. \De\ Signs $664M M&A Deal with Webster Equity Partners

Lifecore Biomedical has entered into a definitive agreement to be acquired by Webster Equity Partners for up to $663.7 million. Common stockholders will receive $6.28 per share in cash at closing plus contingent value rights (CVRs) worth up to an additional $160 million in aggregate based on performance milestones. The transaction represents a 49.5% premium to the company's last closing price and will result in Lifecore becoming a privately held company.

Value
$664M
Counterparty
Webster Equity Partners

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.